CliffBio
small molecule

APRISO

MESALAMINE

Loss of exclusivityMay 2030latest FDA-listed patent expiry
CompanySalix Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameAPRISO
Active ingredientMESALAMINE
Strength375MG
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2008
Marketing statusRX

Listed patents

PatentExpiresType
8865688May 2030use U-1310

More from Salix Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

APRISO patent cliff — loss of exclusivity May 2030 | CliffBio